{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T17:56:06Z","timestamp":1792691766145,"version":"4.5.0"},"reference-count":41,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100011841","name":"Xinxiang Medical University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100011841","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic & Medicinal Chemistry"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.bmc.2026.118757","type":"journal-article","created":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T23:06:36Z","timestamp":1784934396000},"page":"118757","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Discovery of DA1 as PARP inhibitor for the treatment of BRCA-proficient triple negative breast cancer by suppressing the PI3K\/AKT\/mTOR signaling pathway"],"prefix":"10.1016","volume":"141","author":[{"given":"Yan","family":"Qu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lijie","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Song","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liqiang","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bmc.2026.118757_bb0005","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1002\/cncr.28914","article-title":"Subtyping of triple-negative breast cancer: implications for therapy","volume":"121","author":"Abramson","year":"2015","journal-title":"Cancer"},{"key":"10.1016\/j.bmc.2026.118757_bb0010","doi-asserted-by":"crossref","first-page":"2206","DOI":"10.1093\/annonc\/mdt303","article-title":"Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2013","volume":"24","author":"Goldhirsch","year":"2013","journal-title":"Ann Oncol"},{"key":"10.1016\/j.bmc.2026.118757_bb0015","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1002\/path.4280","article-title":"Identification and use of biomarkers in treatment strategies for triple-negative breast cancer subtypes","volume":"232","author":"Lehmann","year":"2014","journal-title":"J Pathol"},{"key":"10.1016\/j.bmc.2026.118757_bb0020","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1038\/nrclinonc.2016.66","article-title":"Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease","volume":"13","author":"Bianchini","year":"2016","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.bmc.2026.118757_bb0025","doi-asserted-by":"crossref","first-page":"2792","DOI":"10.1016\/j.ejca.2009.06.027","article-title":"Triple-negative and HER2-overexpressing breast cancers exhibit an elevated risk and an earlier occurrence of cerebral metastases","volume":"45","author":"Heitz","year":"2009","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.bmc.2026.118757_bb0030","first-page":"93","article-title":"Triple-negative breast cancer: treatment challenges and solutions","volume":"8","author":"Collignon","year":"2016","journal-title":"Breast Cancer (Dove Medical Press)"},{"key":"10.1016\/j.bmc.2026.118757_bb0035","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1186\/s13045-022-01341-0","article-title":"Recent advances in therapeutic strategies for triple-negative breast cancer","volume":"15","author":"Li","year":"2022","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.bmc.2026.118757_bb0040","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1038\/s41392-021-00648-7","article-title":"DNA damage repair: historical perspectives, mechanistic pathways and clinical translation for targeted cancer therapy","volume":"6","author":"Huang","year":"2021","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.bmc.2026.118757_bb0045","doi-asserted-by":"crossref","first-page":"2902","DOI":"10.4161\/cc.7.18.6679","article-title":"DNA repair by nonhomologous end joining and homologous recombination during cell cycle in human cells","volume":"7","author":"Mao","year":"2008","journal-title":"Cell cycle (Georgetown, Tex)"},{"key":"10.1016\/j.bmc.2026.118757_bb0050","doi-asserted-by":"crossref","first-page":"10502","DOI":"10.1074\/jbc.TM118.000371","article-title":"How cells ensure correct repair of DNA double-strand breaks","volume":"293","author":"Her","year":"2018","journal-title":"J Biol Chem"},{"key":"10.1016\/j.bmc.2026.118757_bb0055","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.dnarep.2018.08.019","article-title":"DNA double-strand breaks as drivers of neural genomic change, function, and disease","volume":"71","author":"Alt","year":"2018","journal-title":"DNA Repair (Amst)"},{"key":"10.1016\/j.bmc.2026.118757_bb0060","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1016\/j.trecan.2024.06.008","article-title":"PARPi, BRCA, and gaps: controversies and future research","volume":"10","author":"Dibitetto","year":"2024","journal-title":"Trends Cancer"},{"key":"10.1016\/j.bmc.2026.118757_bb0065","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/S1097-2765(00)80276-2","article-title":"Stable interaction between the products of the BRCA1 and BRCA2 tumor suppressor genes in mitotic and meiotic cells","volume":"2","author":"Chen","year":"1998","journal-title":"Mol Cell"},{"key":"10.1016\/j.bmc.2026.118757_bb0070","doi-asserted-by":"crossref","first-page":"1951","DOI":"10.1101\/gad.1331805","article-title":"Poly(ADP-ribosyl)ation by PARP-1: \u201cPAR-laying\u201d NAD+ into a nuclear signal","volume":"19","author":"Kim","year":"2005","journal-title":"Genes Dev"},{"key":"10.1016\/j.bmc.2026.118757_bb0075","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1038\/nature10760","article-title":"The DNA damage response and cancer therapy","volume":"481","author":"Lord","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.bmc.2026.118757_bb0080","doi-asserted-by":"crossref","first-page":"9575","DOI":"10.1021\/acs.jmedchem.6b00055","article-title":"An update on poly(ADP-ribose)polymerase-1 (PARP-1) inhibitors: opportunities and challenges in Cancer therapy","volume":"59","author":"Wang","year":"2016","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2026.118757_bb0085","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.ejmech.2019.01.024","article-title":"Medicinal chemistry approaches of poly ADP-ribose polymerase 1 (PARP1) inhibitors as anticancer agents - a recent update","volume":"165","author":"Jain","year":"2019","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bmc.2026.118757_bb0090","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2019.107446","article-title":"Delving into PARP inhibition from bench to bedside and back","volume":"206","author":"Grignani","year":"2020","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.bmc.2026.118757_bb0095","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1126\/science.aam7344","article-title":"PARP inhibitors: synthetic lethality in the clinic","volume":"355","author":"Lord","year":"2017","journal-title":"Science"},{"key":"10.1016\/j.bmc.2026.118757_bb0100","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1038\/s41573-020-0076-6","article-title":"Poly(ADP-ribose) polymerase inhibition: past, present and future","volume":"19","author":"Curtin","year":"2020","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.bmc.2026.118757_bb0105","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.breast.2016.05.014","article-title":"Surgery and radiation therapy of triple-negative breast cancers: from biology to clinics","volume":"28","author":"Bernier","year":"2016","journal-title":"Breast (Edinburgh, Scotland)"},{"key":"10.1016\/j.bmc.2026.118757_bb0110","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1186\/s12943-020-01227-0","article-title":"PARP inhibitor resistance: the underlying mechanisms and clinical implications","volume":"19","author":"Li","year":"2020","journal-title":"Mol Cancer"},{"key":"10.1016\/j.bmc.2026.118757_bb0115","doi-asserted-by":"crossref","first-page":"11488","DOI":"10.1021\/acs.jmedchem.4c00113","article-title":"New horizons of synthetic lethality in Cancer: current development and future perspectives","volume":"67","author":"Previtali","year":"2024","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2026.118757_bb0120","doi-asserted-by":"crossref","first-page":"16099","DOI":"10.1021\/acs.jmedchem.2c01352","article-title":"Multi-therapies based on PARP inhibition: potential therapeutic approaches for Cancer treatment","volume":"65","author":"Zhang","year":"2022","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2026.118757_bb0125","doi-asserted-by":"crossref","first-page":"3050","DOI":"10.1242\/dev.137075","article-title":"Proliferation, survival and metabolism: the role of PI3K\/AKT\/mTOR signalling in pluripotency and cell fate determination","volume":"143","author":"Yu","year":"2016","journal-title":"Development"},{"key":"10.1016\/j.bmc.2026.118757_bb0130","doi-asserted-by":"crossref","first-page":"16033","DOI":"10.1021\/acs.jmedchem.2c01070","article-title":"Targeting the PI3K\/AKT\/mTOR Signaling pathway in the treatment of human diseases: current status, trends, and solutions","volume":"65","author":"Huang","year":"2022","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2026.118757_bb0135","doi-asserted-by":"crossref","first-page":"7491","DOI":"10.1073\/pnas.0914242107","article-title":"Nuclear phosphoinositide 3-kinase beta controls double-strand break DNA repair","volume":"107","author":"Kumar","year":"2010","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.bmc.2026.118757_bb0140","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1016\/j.ygyno.2016.07.092","article-title":"Combined inhibition of PI3K and PARP is effective in the treatment of ovarian cancer cells with wild-type PIK3CA genes","volume":"142","author":"Wang","year":"2016","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.bmc.2026.118757_bb0145","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1158\/2159-8290.CD-11-0348","article-title":"PI3K inhibition impairs BRCA1\/2 expression and sensitizes BRCA-proficient triple-negative breast cancer to PARP inhibition","volume":"2","author":"Ibrahim","year":"2012","journal-title":"Cancer Discov"},{"key":"10.1016\/j.bmc.2026.118757_bb0150","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1158\/2159-8290.CD-11-0336","article-title":"Combining a PI3K inhibitor with a PARP inhibitor provides an effective therapy for BRCA1-related breast cancer","volume":"2","author":"Juvekar","year":"2012","journal-title":"Cancer Discov"},{"key":"10.1016\/j.bmc.2026.118757_bb0155","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1021\/acs.jmedchem.9b00622","article-title":"Discovery of novel dual poly(ADP-ribose)polymerase and phosphoinositide 3-kinase inhibitors as a promising strategy for Cancer therapy","volume":"63","author":"Wang","year":"2020","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2026.118757_bb0160","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.113054","article-title":"Discovery of novel PARP\/PI3K dual inhibitors with high efficiency against BRCA-proficient triple negative breast cancer","volume":"213","author":"Wang","year":"2021","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bmc.2026.118757_bb0165","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1080\/17460441.2017.1303478","article-title":"Using natural products for drug discovery: the impact of the genomics era","volume":"12","author":"Zhang","year":"2017","journal-title":"Expert Opin Drug Discov"},{"key":"10.1016\/j.bmc.2026.118757_bb0170","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.fitote.2015.04.012","article-title":"Insights into drug discovery from natural products through structural modification","volume":"103","author":"Chen","year":"2015","journal-title":"Fitoterapia"},{"key":"10.1016\/j.bmc.2026.118757_bb0175","doi-asserted-by":"crossref","first-page":"4735","DOI":"10.2147\/DDDT.S266911","article-title":"Pharmacological activity and mechanism of Tanshinone IIA in related diseases","volume":"14","author":"Guo","year":"2020","journal-title":"Drug Des Devel Ther"},{"key":"10.1016\/j.bmc.2026.118757_bb0180","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.2174\/0929867328666211108110025","article-title":"Tanshinone IIA: pharmacology, Total synthesis, and Progress in structure-modifications","volume":"29","author":"Huang","year":"2022","journal-title":"Curr Med Chem"},{"key":"10.1016\/j.bmc.2026.118757_bb0185","doi-asserted-by":"crossref","first-page":"19268","DOI":"10.1038\/s41598-021-98948-z","article-title":"Tanshinone IIA affects the malignant growth of cholangiocarcinoma cells by inhibiting the PI3K-Akt-mTOR pathway","volume":"11","author":"Liu","year":"2021","journal-title":"Sci Rep"},{"key":"10.1016\/j.bmc.2026.118757_bb0190","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1186\/s12906-024-04363-y","article-title":"Tanshinone IIA inhibits proliferation and migration by downregulation of the PI3K\/Akt pathway in small cell lung cancer cells","volume":"24","author":"Jiang","year":"2024","journal-title":"BMC Complementary Med Ther"},{"key":"10.1016\/j.bmc.2026.118757_bb0195","first-page":"2995","article-title":"Tanshinone IIA induces apoptosis and autophagy in acute monocytic leukemia via downregulation of PI3K\/Akt pathway","volume":"11","author":"Zhang","year":"2019","journal-title":"Am J Transl Res"},{"key":"10.1016\/j.bmc.2026.118757_bb0200","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1007\/s12672-025-02152-8","article-title":"Tanshinone IIA affects the proliferation of A549\/tax by affecting the expression of MMP7 through the PI3K-AKT-mTOR signaling pathway","volume":"16","author":"Chen","year":"2025","journal-title":"Discov Oncol"},{"key":"10.1016\/j.bmc.2026.118757_bb0205","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.113708","article-title":"Design, synthesis and biological evaluation of tanshinone IIA-based analogues: potent inhibitors of microtubule formation and angiogenesis","volume":"224","author":"Huang","year":"2021","journal-title":"Eur J Med Chem"}],"container-title":["Bioorganic & Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0968089626002130?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0968089626002130?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T11:22:28Z","timestamp":1786015348000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0968089626002130"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":41,"alternative-id":["S0968089626002130"],"URL":"https:\/\/doi.org\/10.1016\/j.bmc.2026.118757","relation":{},"ISSN":["0968-0896"],"issn-type":[{"value":"0968-0896","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Discovery of DA1 as PARP inhibitor for the treatment of BRCA-proficient triple negative breast cancer by suppressing the PI3K\/AKT\/mTOR signaling pathway","name":"articletitle","label":"Article Title"},{"value":"Bioorganic & Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bmc.2026.118757","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"118757"}}